Company news
Amarantus Bioscience Holdings, Inc. news in 2017
Amarantus Bioscience Holdings, Inc.'s news releases, calls and decks from 2017, newest first.
Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma
December 26, 2017
Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease
December 20, 2017
Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF
December 14, 2017
Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
December 11, 2017
Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID
December 7, 2017
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive Impairment Associated with Alzheimer’s Disease and Parkinson’s disea
December 6, 2017
Amarantus Provides Comprehensive Corporate Update •
December 6, 2017
Amarantus Enters into Forbearance and Capital Restructuring Agreements with Holders of Secured Debt, Convertible Preferred Stock and Warrants
December 6, 2017
Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
April 17, 2017
Amarantus Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc.
April 5, 2017
Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc.
February 27, 2017
Amarantus Announces Passing of Biotechnology Legend Dr. Joseph Rubinfeld
February 10, 2017